nodes	percent_of_prediction	percent_of_DWPC	metapath
Ramelteon—CYP1A2—Imiquimod—skin cancer	0.187	0.21	CbGbCtD
Ramelteon—CYP2C19—Vismodegib—skin cancer	0.141	0.158	CbGbCtD
Ramelteon—CYP1A2—Vemurafenib—skin cancer	0.103	0.115	CbGbCtD
Ramelteon—CYP3A4—Temozolomide—skin cancer	0.0982	0.11	CbGbCtD
Ramelteon—CYP3A4—Imiquimod—skin cancer	0.0982	0.11	CbGbCtD
Ramelteon—CYP1A2—Dacarbazine—skin cancer	0.0787	0.0882	CbGbCtD
Ramelteon—CYP3A4—Vismodegib—skin cancer	0.068	0.0763	CbGbCtD
Ramelteon—CYP3A4—Vemurafenib—skin cancer	0.0538	0.0603	CbGbCtD
Ramelteon—CYP1A2—Fluorouracil—skin cancer	0.0461	0.0517	CbGbCtD
Ramelteon—CYP3A4—Docetaxel—skin cancer	0.0185	0.0207	CbGbCtD
Ramelteon—MTNR1A—Small Ligand GPCRs—PTGER4—skin cancer	0.00505	0.134	CbGpPWpGaD
Ramelteon—MTNR1B—Small Ligand GPCRs—PTGER4—skin cancer	0.00505	0.134	CbGpPWpGaD
Ramelteon—Dysgeusia—Vismodegib—skin cancer	0.0025	0.0356	CcSEcCtD
Ramelteon—Myalgia—Vismodegib—skin cancer	0.00217	0.031	CcSEcCtD
Ramelteon—Arthralgia—Vismodegib—skin cancer	0.00217	0.031	CcSEcCtD
Ramelteon—Influenza—Imiquimod—skin cancer	0.00193	0.0275	CcSEcCtD
Ramelteon—Musculoskeletal discomfort—Vismodegib—skin cancer	0.0019	0.0271	CcSEcCtD
Ramelteon—Fatigue—Vismodegib—skin cancer	0.0018	0.0256	CcSEcCtD
Ramelteon—Upper respiratory tract infection—Imiquimod—skin cancer	0.00179	0.0256	CcSEcCtD
Ramelteon—Depression—Imiquimod—skin cancer	0.00172	0.0245	CcSEcCtD
Ramelteon—Mental disability—Temozolomide—skin cancer	0.0016	0.0228	CcSEcCtD
Ramelteon—Dysgeusia—Vemurafenib—skin cancer	0.00154	0.022	CcSEcCtD
Ramelteon—Asthenia—Vismodegib—skin cancer	0.0015	0.0213	CcSEcCtD
Ramelteon—MTNR1B—Circadian rythm related genes—NKX2-1—skin cancer	0.00144	0.0381	CbGpPWpGaD
Ramelteon—MTNR1A—Circadian rythm related genes—NKX2-1—skin cancer	0.00144	0.0381	CbGpPWpGaD
Ramelteon—Diarrhoea—Vismodegib—skin cancer	0.00143	0.0203	CcSEcCtD
Ramelteon—Myalgia—Vemurafenib—skin cancer	0.00134	0.0191	CcSEcCtD
Ramelteon—Arthralgia—Vemurafenib—skin cancer	0.00134	0.0191	CcSEcCtD
Ramelteon—Anaphylactic shock—Vemurafenib—skin cancer	0.00129	0.0184	CcSEcCtD
Ramelteon—Nausea—Vismodegib—skin cancer	0.00124	0.0176	CcSEcCtD
Ramelteon—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00117	0.0167	CcSEcCtD
Ramelteon—Myalgia—Imiquimod—skin cancer	0.00115	0.0163	CcSEcCtD
Ramelteon—Arthralgia—Imiquimod—skin cancer	0.00115	0.0163	CcSEcCtD
Ramelteon—Fatigue—Vemurafenib—skin cancer	0.00111	0.0158	CcSEcCtD
Ramelteon—Upper respiratory tract infection—Temozolomide—skin cancer	0.00108	0.0153	CcSEcCtD
Ramelteon—Depression—Temozolomide—skin cancer	0.00103	0.0147	CcSEcCtD
Ramelteon—Musculoskeletal discomfort—Imiquimod—skin cancer	0.001	0.0143	CcSEcCtD
Ramelteon—Insomnia—Imiquimod—skin cancer	0.000993	0.0142	CcSEcCtD
Ramelteon—Upper respiratory tract infection—Fluorouracil—skin cancer	0.000991	0.0141	CcSEcCtD
Ramelteon—Somnolence—Imiquimod—skin cancer	0.000976	0.0139	CcSEcCtD
Ramelteon—MTNR1B—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000954	0.0253	CbGpPWpGaD
Ramelteon—MTNR1A—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000954	0.0253	CbGpPWpGaD
Ramelteon—Fatigue—Imiquimod—skin cancer	0.000947	0.0135	CcSEcCtD
Ramelteon—Asthenia—Vemurafenib—skin cancer	0.000924	0.0132	CcSEcCtD
Ramelteon—Diarrhoea—Vemurafenib—skin cancer	0.000881	0.0126	CcSEcCtD
Ramelteon—MTNR1B—GPCR ligand binding—PTCH2—skin cancer	0.000861	0.0228	CbGpPWpGaD
Ramelteon—MTNR1A—GPCR ligand binding—PTCH2—skin cancer	0.000861	0.0228	CbGpPWpGaD
Ramelteon—Dizziness—Vemurafenib—skin cancer	0.000851	0.0121	CcSEcCtD
Ramelteon—MTNR1A—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000817	0.0217	CbGpPWpGaD
Ramelteon—MTNR1B—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000817	0.0217	CbGpPWpGaD
Ramelteon—Myalgia—Bleomycin—skin cancer	0.000814	0.0116	CcSEcCtD
Ramelteon—Headache—Vemurafenib—skin cancer	0.000806	0.0115	CcSEcCtD
Ramelteon—Dysgeusia—Temozolomide—skin cancer	0.000789	0.0113	CcSEcCtD
Ramelteon—Asthenia—Imiquimod—skin cancer	0.000788	0.0112	CcSEcCtD
Ramelteon—Anaphylactic shock—Bleomycin—skin cancer	0.00078	0.0111	CcSEcCtD
Ramelteon—Nausea—Vemurafenib—skin cancer	0.000765	0.0109	CcSEcCtD
Ramelteon—Myalgia—Dactinomycin—skin cancer	0.000759	0.0108	CcSEcCtD
Ramelteon—Diarrhoea—Imiquimod—skin cancer	0.000751	0.0107	CcSEcCtD
Ramelteon—Dizziness—Imiquimod—skin cancer	0.000726	0.0104	CcSEcCtD
Ramelteon—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000711	0.0101	CcSEcCtD
Ramelteon—Headache—Imiquimod—skin cancer	0.000688	0.00981	CcSEcCtD
Ramelteon—Myalgia—Temozolomide—skin cancer	0.000686	0.00978	CcSEcCtD
Ramelteon—Arthralgia—Temozolomide—skin cancer	0.000686	0.00978	CcSEcCtD
Ramelteon—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000663	0.00945	CcSEcCtD
Ramelteon—Anaphylactic shock—Temozolomide—skin cancer	0.000658	0.00938	CcSEcCtD
Ramelteon—Nausea—Imiquimod—skin cancer	0.000652	0.0093	CcSEcCtD
Ramelteon—Myalgia—Fluorouracil—skin cancer	0.000632	0.00902	CcSEcCtD
Ramelteon—MTNR1A—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000627	0.0166	CbGpPWpGaD
Ramelteon—MTNR1B—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000627	0.0166	CbGpPWpGaD
Ramelteon—Fatigue—Dactinomycin—skin cancer	0.000627	0.00894	CcSEcCtD
Ramelteon—MTNR1A—GPCR ligand binding—MC1R—skin cancer	0.000622	0.0165	CbGpPWpGaD
Ramelteon—MTNR1B—GPCR ligand binding—MC1R—skin cancer	0.000622	0.0165	CbGpPWpGaD
Ramelteon—Anaphylactic shock—Fluorouracil—skin cancer	0.000606	0.00864	CcSEcCtD
Ramelteon—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000599	0.00855	CcSEcCtD
Ramelteon—Insomnia—Temozolomide—skin cancer	0.000595	0.00848	CcSEcCtD
Ramelteon—Somnolence—Temozolomide—skin cancer	0.000585	0.00834	CcSEcCtD
Ramelteon—Fatigue—Temozolomide—skin cancer	0.000567	0.00809	CcSEcCtD
Ramelteon—Asthenia—Bleomycin—skin cancer	0.00056	0.00798	CcSEcCtD
Ramelteon—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000552	0.00787	CcSEcCtD
Ramelteon—Insomnia—Fluorouracil—skin cancer	0.000548	0.00782	CcSEcCtD
Ramelteon—Somnolence—Fluorouracil—skin cancer	0.000539	0.00768	CcSEcCtD
Ramelteon—MTNR1A—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000537	0.0143	CbGpPWpGaD
Ramelteon—MTNR1B—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000537	0.0143	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—RHOU—skin cancer	0.000534	0.0142	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—RHOU—skin cancer	0.000534	0.0142	CbGpPWpGaD
Ramelteon—Dysgeusia—Docetaxel—skin cancer	0.000525	0.00748	CcSEcCtD
Ramelteon—Asthenia—Dactinomycin—skin cancer	0.000522	0.00744	CcSEcCtD
Ramelteon—Diarrhoea—Dactinomycin—skin cancer	0.000498	0.0071	CcSEcCtD
Ramelteon—Asthenia—Temozolomide—skin cancer	0.000472	0.00673	CcSEcCtD
Ramelteon—Nausea—Bleomycin—skin cancer	0.000463	0.00661	CcSEcCtD
Ramelteon—Arthralgia—Docetaxel—skin cancer	0.000456	0.00651	CcSEcCtD
Ramelteon—Myalgia—Docetaxel—skin cancer	0.000456	0.00651	CcSEcCtD
Ramelteon—Diarrhoea—Temozolomide—skin cancer	0.00045	0.00642	CcSEcCtD
Ramelteon—MTNR1B—GPCR ligand binding—SHH—skin cancer	0.000443	0.0118	CbGpPWpGaD
Ramelteon—MTNR1A—GPCR ligand binding—SHH—skin cancer	0.000443	0.0118	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling by GPCR—PTCH2—skin cancer	0.000442	0.0117	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling by GPCR—PTCH2—skin cancer	0.000442	0.0117	CbGpPWpGaD
Ramelteon—Anaphylactic shock—Docetaxel—skin cancer	0.000438	0.00624	CcSEcCtD
Ramelteon—Dizziness—Temozolomide—skin cancer	0.000435	0.0062	CcSEcCtD
Ramelteon—Nausea—Dactinomycin—skin cancer	0.000432	0.00616	CcSEcCtD
Ramelteon—MTNR1B—GPCR ligand binding—SMO—skin cancer	0.00042	0.0111	CbGpPWpGaD
Ramelteon—MTNR1A—GPCR ligand binding—PTCH1—skin cancer	0.00042	0.0111	CbGpPWpGaD
Ramelteon—MTNR1B—GPCR ligand binding—PTCH1—skin cancer	0.00042	0.0111	CbGpPWpGaD
Ramelteon—MTNR1A—GPCR ligand binding—SMO—skin cancer	0.00042	0.0111	CbGpPWpGaD
Ramelteon—Diarrhoea—Fluorouracil—skin cancer	0.000415	0.00591	CcSEcCtD
Ramelteon—Headache—Temozolomide—skin cancer	0.000412	0.00588	CcSEcCtD
Ramelteon—MTNR1A—GPCR ligand binding—PTGER4—skin cancer	0.000409	0.0109	CbGpPWpGaD
Ramelteon—MTNR1B—GPCR ligand binding—PTGER4—skin cancer	0.000409	0.0109	CbGpPWpGaD
Ramelteon—MTNR1A—Circadian rythm related genes—CDK4—skin cancer	0.000404	0.0107	CbGpPWpGaD
Ramelteon—MTNR1B—Circadian rythm related genes—CDK4—skin cancer	0.000404	0.0107	CbGpPWpGaD
Ramelteon—Dizziness—Fluorouracil—skin cancer	0.000401	0.00572	CcSEcCtD
Ramelteon—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000399	0.00568	CcSEcCtD
Ramelteon—Insomnia—Docetaxel—skin cancer	0.000396	0.00564	CcSEcCtD
Ramelteon—Nausea—Temozolomide—skin cancer	0.000391	0.00557	CcSEcCtD
Ramelteon—Somnolence—Docetaxel—skin cancer	0.000389	0.00555	CcSEcCtD
Ramelteon—Headache—Fluorouracil—skin cancer	0.00038	0.00541	CcSEcCtD
Ramelteon—Fatigue—Docetaxel—skin cancer	0.000377	0.00538	CcSEcCtD
Ramelteon—Nausea—Fluorouracil—skin cancer	0.00036	0.00513	CcSEcCtD
Ramelteon—MTNR1B—GPCR downstream signaling—MC1R—skin cancer	0.000352	0.00933	CbGpPWpGaD
Ramelteon—MTNR1A—GPCR downstream signaling—MC1R—skin cancer	0.000352	0.00933	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling by GPCR—MC1R—skin cancer	0.000319	0.00847	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling by GPCR—MC1R—skin cancer	0.000319	0.00847	CbGpPWpGaD
Ramelteon—Asthenia—Docetaxel—skin cancer	0.000314	0.00448	CcSEcCtD
Ramelteon—Diarrhoea—Docetaxel—skin cancer	0.000299	0.00427	CcSEcCtD
Ramelteon—Dizziness—Docetaxel—skin cancer	0.000289	0.00412	CcSEcCtD
Ramelteon—Headache—Docetaxel—skin cancer	0.000274	0.00391	CcSEcCtD
Ramelteon—MTNR1A—Signaling Pathways—PTCH2—skin cancer	0.000261	0.00692	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—PTCH2—skin cancer	0.000261	0.00692	CbGpPWpGaD
Ramelteon—Nausea—Docetaxel—skin cancer	0.00026	0.00371	CcSEcCtD
Ramelteon—MTNR1B—GPCR downstream signaling—PTGER4—skin cancer	0.000231	0.00613	CbGpPWpGaD
Ramelteon—MTNR1A—GPCR downstream signaling—PTGER4—skin cancer	0.000231	0.00613	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling by GPCR—SHH—skin cancer	0.000228	0.00603	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling by GPCR—SHH—skin cancer	0.000228	0.00603	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling by GPCR—SMO—skin cancer	0.000216	0.00572	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling by GPCR—SMO—skin cancer	0.000216	0.00572	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling by GPCR—PTCH1—skin cancer	0.000216	0.00572	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling by GPCR—PTCH1—skin cancer	0.000216	0.00572	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling by GPCR—PTGER4—skin cancer	0.00021	0.00557	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling by GPCR—PTGER4—skin cancer	0.00021	0.00557	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—GLI2—skin cancer	0.000198	0.00524	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—GLI2—skin cancer	0.000198	0.00524	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—MC1R—skin cancer	0.000189	0.005	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—MC1R—skin cancer	0.000189	0.005	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—GLI1—skin cancer	0.000186	0.00493	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—GLI1—skin cancer	0.000186	0.00493	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—SUFU—skin cancer	0.000176	0.00467	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—SUFU—skin cancer	0.000176	0.00467	CbGpPWpGaD
Ramelteon—MTNR1A—Circadian rythm related genes—TP53—skin cancer	0.000172	0.00456	CbGpPWpGaD
Ramelteon—MTNR1B—Circadian rythm related genes—TP53—skin cancer	0.000172	0.00456	CbGpPWpGaD
Ramelteon—MTNR1A—Circadian rythm related genes—IL6—skin cancer	0.000157	0.00418	CbGpPWpGaD
Ramelteon—MTNR1B—Circadian rythm related genes—IL6—skin cancer	0.000157	0.00418	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—SHH—skin cancer	0.000134	0.00356	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—SHH—skin cancer	0.000134	0.00356	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—RASA1—skin cancer	0.000134	0.00354	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—RASA1—skin cancer	0.000134	0.00354	CbGpPWpGaD
Ramelteon—CYP2C19—Arachidonic acid metabolism—PTGS2—skin cancer	0.000128	0.0034	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—SMO—skin cancer	0.000127	0.00338	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—SMO—skin cancer	0.000127	0.00338	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—PTCH1—skin cancer	0.000127	0.00338	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—PTCH1—skin cancer	0.000127	0.00338	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—PTGER4—skin cancer	0.000124	0.00329	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—PTGER4—skin cancer	0.000124	0.00329	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—FOXO4—skin cancer	0.00011	0.00291	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—FOXO4—skin cancer	0.00011	0.00291	CbGpPWpGaD
Ramelteon—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	0.000107	0.00283	CbGpPWpGaD
Ramelteon—CYP1A2—Arachidonic acid metabolism—PTGS2—skin cancer	9.99e-05	0.00265	CbGpPWpGaD
Ramelteon—CYP2C19—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	9.6e-05	0.00255	CbGpPWpGaD
Ramelteon—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	8.31e-05	0.0022	CbGpPWpGaD
Ramelteon—CYP1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	7.48e-05	0.00198	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—TERT—skin cancer	7.32e-05	0.00194	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—TERT—skin cancer	7.32e-05	0.00194	CbGpPWpGaD
Ramelteon—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	7.15e-05	0.0019	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling by GPCR—NRAS—skin cancer	6.17e-05	0.00164	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling by GPCR—NRAS—skin cancer	6.17e-05	0.00164	CbGpPWpGaD
Ramelteon—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	6.08e-05	0.00161	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—BRAF—skin cancer	5.8e-05	0.00154	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—BRAF—skin cancer	5.8e-05	0.00154	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling by GPCR—KRAS—skin cancer	5.31e-05	0.00141	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling by GPCR—KRAS—skin cancer	5.31e-05	0.00141	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling by GPCR—HRAS—skin cancer	4.51e-05	0.0012	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling by GPCR—HRAS—skin cancer	4.51e-05	0.0012	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling by GPCR—IL6—skin cancer	4.32e-05	0.00115	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling by GPCR—IL6—skin cancer	4.32e-05	0.00115	CbGpPWpGaD
Ramelteon—CYP2C19—Metabolism—PLIN2—skin cancer	4.28e-05	0.00113	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—NRAS—skin cancer	3.64e-05	0.000966	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—NRAS—skin cancer	3.64e-05	0.000966	CbGpPWpGaD
Ramelteon—CYP2C19—Metabolism—CSPG4—skin cancer	3.45e-05	0.000914	CbGpPWpGaD
Ramelteon—CYP1A2—Metabolism—PLIN2—skin cancer	3.33e-05	0.000884	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—KRAS—skin cancer	3.14e-05	0.000831	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—KRAS—skin cancer	3.14e-05	0.000831	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—TP53—skin cancer	2.79e-05	0.000739	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—TP53—skin cancer	2.79e-05	0.000739	CbGpPWpGaD
Ramelteon—CYP1A2—Metabolism—CSPG4—skin cancer	2.69e-05	0.000712	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—HRAS—skin cancer	2.66e-05	0.000707	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—HRAS—skin cancer	2.66e-05	0.000707	CbGpPWpGaD
Ramelteon—CYP3A4—Metabolism—PLIN2—skin cancer	2.57e-05	0.000682	CbGpPWpGaD
Ramelteon—MTNR1A—Signaling Pathways—IL6—skin cancer	2.55e-05	0.000676	CbGpPWpGaD
Ramelteon—MTNR1B—Signaling Pathways—IL6—skin cancer	2.55e-05	0.000676	CbGpPWpGaD
Ramelteon—CYP2C19—Metabolism—ENO2—skin cancer	2.34e-05	0.000621	CbGpPWpGaD
Ramelteon—CYP3A4—Metabolism—CSPG4—skin cancer	2.07e-05	0.00055	CbGpPWpGaD
Ramelteon—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.83e-05	0.000486	CbGpPWpGaD
Ramelteon—CYP1A2—Metabolism—ENO2—skin cancer	1.83e-05	0.000484	CbGpPWpGaD
Ramelteon—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.43e-05	0.000379	CbGpPWpGaD
Ramelteon—CYP3A4—Metabolism—ENO2—skin cancer	1.41e-05	0.000374	CbGpPWpGaD
Ramelteon—CYP2C19—Metabolism—ERCC2—skin cancer	1.36e-05	0.000361	CbGpPWpGaD
Ramelteon—CYP1A2—Metabolism—ERCC2—skin cancer	1.06e-05	0.000281	CbGpPWpGaD
Ramelteon—CYP3A4—Metabolism—ERCC2—skin cancer	8.19e-06	0.000217	CbGpPWpGaD
Ramelteon—CYP2C19—Metabolism—PTGS2—skin cancer	8.16e-06	0.000216	CbGpPWpGaD
Ramelteon—CYP1A2—Metabolism—PTGS2—skin cancer	6.36e-06	0.000169	CbGpPWpGaD
Ramelteon—CYP3A4—Metabolism—PTGS2—skin cancer	4.91e-06	0.00013	CbGpPWpGaD
